Organization Profile

You just read:

Oncothyreon Announces that L-BLP25 (Stimuvax®) Did Not Meet Primary Endpoint of Improvement in Overall Survival in Pivotal Phase 3 Trial in Patients with Non-Small Cell Lung Cancer

News provided by

Oncothyreon Inc.

Dec 19, 2012, 06:30 ET